Updated software improves slicing for large-format 3D printing
Researchers at Oak Ridge National Laboratory have empirically quantified the shifts in routine daytime activities, such as getting a morning coffee or takeaway dinner, following safer at home orders during the early days of the COVID-19 pandemic.
Several electrolyte and thin-film coating technologies, developed at Oak Ridge National Laboratory, have been licensed by BTRY, a battery technology company based in Virginia, to make batteries with increased energy density, at lower cost, and with an improved safety profile in crashes.
Oak Ridge National Laboratory researchers collaborated with Iowa State University and RJ Lee Group to demonstrate a safe and effective antiviral coating for N95 masks. The coating destroys the COVID-19-causing coronavirus and could enable reuse of masks made from various fabrics.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
To explore the inner workings of severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, researchers from ORNL developed a novel technique.
Oak Ridge National Laboratory researchers have retrofitted a commercial refrigeration container designed to ensure COVID-19 vaccines remain at ultra-low temperatures during long transport and while locally stored.
A study by Department of Energy researchers detailed a potential method to detect the novel coronavirus
Research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2021 R&D 100 Awards, plus special recognition for a COVID-19-related project.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.